Table 2 Summary ORs and 95% CI of IL-10 −1082A > G and −819T > C and −592A > C polymorphisms and head and neck cancer risk.

From: Increased risks between Interleukin-10 gene polymorphisms and haplotype and head and neck cancer: a meta-analysis

−1082 A>G	N^*	G vs. A				AG vs. AA				GG vs. AA				AG + GG vs. AA				GG vs. AA + AG
−1082 A>G	N^*	OR	95% CI	P	I ²	OR	95% CI	P	I ²	OR	95% CI	P	I ²	OR	95% CI	P	I ²	OR	95% CI	P	I ²
Total	9	1.56	1.27–1.92	<0.01	69.4	1.64	1.32–2.05	<0.01	55.6	2.24	1.69–2.97	<0.01	38.5	1.70	1.36–2.14	<0.01	61.8	1.89	1.23–2.90	0.01	46.3
HWE-yes	3	1.05	0.81–1.37	0.71	0	0.99	0.71–1.38	0.95	0	1.29	0.64–2.58	0.49	0	1.02	0.74–1.41	0.88	0	1.18	0.63–2.22	0.60	0
HWE-no	6	1.82	1.51–2.19	<0.01	54.4	1.94	1.67–2.25	<0.01	0	2.54	1.57–4.12	<0.01	48.0	2.04	1.77–2.35	<0.01	0.4	2.12	1.24–3.60	0.01	58.5
Ethnicity
Caucasian	3	1.34	0.93–1.93	0.12	67.9	1.76	1.05–2.94	0.03	65.3	1.17	0.72–1.90	0.53	0	1.69	0.98–2.90	0.06	71.5	0.95	0.61–1.49	0.84	0
Asian	6	1.72	1.37–2.15	<0.01	60.7	1.59	1.22–2.07	<0.01	58.7	3.15	2.21–4.51	<0.01	0	1.70	1.31–2.23	<0.01	63.6	2.73	1.92–3.89	<0.01	0
Design
PC	6	1.47	1.10–1.96	0.01	70.5	1.62	1.15–2.28	0.01	62.2	1.72	1.18–2.49	<0.01	37.1	1.65	1.17–2.33	<0.01	66.1	1.51	0.89–2.57	0.13	41.4
HC	3	1.73	1.28–2.34	<0.01	65.4	1.64	1.19–2.26	<0.01	58.4	3.24	2.09–5.02	<0.01	0	1.74	1.24–2.45	<0.01	66.4	2.80	1.81–4.33	<0.01	0
Cancer location
Oral	4	1.76	1.36–2.27	<0.01	55.2	1.71	1.15–2.54	0.01	71.1	3.13	2.06–4.77	<0.01	0	1.83	1.26–2.66	<0.01	70.1	2.69	1.77–4.09	<0.01	0
Nasopharyngeal	4	1.53	1.06–2.20	0.02	76.5	1.75	1.38–2.21	<0.01	5.2	1.81	0.94–3.48	0.07	60.3	1.74	1.28–2.36	<0.01	44.9	1.52	0.79–2.90	0.21	64.2
−819 T>C		C vs. T				TC vs. TT				CC vs. TT				TC + CC vs.TT				CC vs. TT + TC
Total	6	1.15	1.04–1.21	0.01	20.1	1.24	0.93–1.65	0.14	65.8	1.28	1.03–1.59	0.03	0	1.27	0.99–1.64	0.06	62.0	1.19	0.98–1.45	0.08	0
HWE-yes	4	1.24	1.07–1.45	0.01	33.3	1.33	0.75–2.37	0.33	78.3	1.53	1.08–2.15	0.02	0	1.41	0.86–2.32	0.18	73.8	1.31	0.99–1.75	0.06	0
HWE-no	2	1.09	0.96–1.24	0.20	0	1.11	0.93–1.33	0.24	0	1.13	0.85–1.50	0.40	0	1.12	0.95–1.32	0.19	0	1.08	0.82–1.42	0.57	0
Ethnicity
Asian	5	1.16	1.05–1.28	<0.01	29.7	1.27	0.94–1.71	0.12	72.0	1.30	1.04–1.61	0.02	0	1.30	0.99–1.70	0.06	68.7	1.22	0.99–1.51	0.07	0
Design
PC	4	1.24	1.07–1.45	0.01	33.3	1.33	0.75–2.37	0.33	78.3	1.53	1.08–2.15	0.02	0	1.41	0.86–2.32	0.18	73.8	1.31	0.99–1.75	0.06	0
HC	2	1.09	0.96–1.24	0.20	0	1.11	0.93–1.33	0.24	0	1.13	0.85–1.50	0.40	0	1.12	0.95–1.32	0.19	0	1.08	0.82–1.42	0.57	0
Cancer location
Oral	3	1.23	0.98–1.54	0.08	63.6	1.44	085–2.44	0.18	85.5	1.6	0.97–1.63	0.09	2.4	1.45	0.90–2.35	0.13	84.3	1.17	0.91–1.50	0.22	0
Nasopharyngeal	3	1.15	0.96–1.37	0.13	0	1.10	0.84–1.44	0.49	0	1.33	0.90–1.96	0.15	0	1.16	0.90–1.49	0.25	0	1.22	0.89–1.67	0.22	0
–592 A>C		C vs. A				AC vs. AA				CC vs. AA				AC+CC vs. AA				CC vs. AA+AC
Total	6	1.11	0.94–1.31	0.22	55.6	1.14	0.84–1.55	0.41	71.2	1.14	0.92–1.41	0.24	22.3	1.17	0.88–1.57	0.29	71.3	1.11	0.92–1.36	0.28	0
HWE-yes	5	1.16	0.95–1.42	0.14	52.3	1.21	0.79–1.87	0.38	74.9	1.31	0.98–1.76	0.07	8.9	1.26	0.85–1.88	0.26	73.4	1.22	0.94–1.56	0.13	0
Ethnicity
Asian	5	1.13	0.94–1.36	0.22	64.0	1.16	0.84–1.62	0.36	76.7	1.15	0.92–1.43	0.21	35.1	1.20	0.88–1.63	0.25	76.8	1.13	0.92–1.40	0.25	8.5
Design
PC	4	1.24	1.07–1.45	0.01	33.3	1.33	0.75–2.37	0.33	78.3	1.53	1.08–2.15	0.02	0	1.41	0.86–2.32	0.18	73.8	1.31	0.99–1.75	0.06	0
HC	2	0.95	0.84–1.08	0.47	0	0.94	0.79–1.12	0.51	0	0.93	0.70–1.24	0.62	0	0.94	0.80–1.11	0.46	0	0.95	0.73–1.26	0.74	0
Cancer location
Oral	3	1.20	0.90–1.60	0.22	77.2	1.09	0.92–1.28	0.32	87.8	1.24	0.82–1.88	0.30	45.5	1.40	0.82–2.40	0.22	87.5	1.10	0.86–1.41	0.46	0
Nasopharyngeal	3	1.03	0.87–1.24	0.71	16.3	0.94	0.72–1.23	0.65	0	1.14	0.77–1.69	0.50	27.8	0.99	0.77–1.27	0.91	0	1.14	0.83–1.57	0.42	25.5

PC: Population control HC: Hospital control.
*Numbers of comparisons.

Back to article page

Table 2 Summary ORs and 95% CI of IL-10 −1082A > G and −819T > C and −592A > C polymorphisms and head and neck cancer risk.

Search

Quick links